The University of Chicago Header Logo

Connection

John Hart to Colonic Neoplasms

This is a "connection" page, showing publications John Hart has written about Colonic Neoplasms.
Connection Strength

2.811
  1. Loss of microfibril-associated protein 5 (MFAP5) expression in colon cancer stroma. Virchows Arch. 2020 Mar; 476(3):383-390.
    View in: PubMed
    Score: 0.447
  2. Identification of histologically distinct conventional adenomas that arise predominately in patients with sessile serrated adenomas. Am J Surg Pathol. 2010 Mar; 34(3):355-63.
    View in: PubMed
    Score: 0.232
  3. Upregulation of polycistronic microRNA-143 and microRNA-145 in colonocytes suppresses colitis and inflammation-associated colon cancer. Epigenetics. 2021 12; 16(12):1317-1334.
    View in: PubMed
    Score: 0.123
  4. A novel mouse model of sporadic colon cancer induced by combination of conditional Apc genes and chemical carcinogen in the absence of Cre recombinase. Carcinogenesis. 2019 11 25; 40(11):1376-1386.
    View in: PubMed
    Score: 0.114
  5. Losartan and Vitamin D Inhibit Colonic Tumor Development in a Conditional Apc-Deleted Mouse Model of Sporadic Colon Cancer. Cancer Prev Res (Phila). 2019 07; 12(7):433-448.
    View in: PubMed
    Score: 0.110
  6. Early increase in blood supply (EIBS) is associated with tumor risk in the Azoxymethane model of colon cancer. BMC Cancer. 2018 Aug 13; 18(1):814.
    View in: PubMed
    Score: 0.104
  7. Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. Clin Gastroenterol Hepatol. 2019 01; 17(1):205-206.
    View in: PubMed
    Score: 0.102
  8. Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointest Endosc. 2018 May; 87(5):1304-1309.
    View in: PubMed
    Score: 0.100
  9. miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis-Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD. Clin Cancer Res. 2017 Sep 01; 23(17):5281-5291.
    View in: PubMed
    Score: 0.096
  10. Daikenchuto (TU-100) Suppresses Tumor Development in the Azoxymethane and APCmin/+ Mouse Models of Experimental Colon Cancer. Phytother Res. 2017 Jan; 31(1):90-99.
    View in: PubMed
    Score: 0.092
  11. ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet-associated Colon Cancer. Clin Cancer Res. 2017 Jan 15; 23(2):549-561.
    View in: PubMed
    Score: 0.090
  12. Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis. 2016 Mar; 22(3):631-7.
    View in: PubMed
    Score: 0.088
  13. The renin-angiotensin system mediates EGF receptor-vitamin d receptor cross-talk in colitis-associated colon cancer. Clin Cancer Res. 2014 Nov 15; 20(22):5848-5859.
    View in: PubMed
    Score: 0.079
  14. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1601-8.e1-4.
    View in: PubMed
    Score: 0.073
  15. Both stromal cell and colonocyte epidermal growth factor receptors control HCT116 colon cancer cell growth in tumor xenografts. Carcinogenesis. 2012 Oct; 33(10):1930-9.
    View in: PubMed
    Score: 0.068
  16. American ginseng suppresses Western diet-promoted tumorigenesis in model of inflammation-associated colon cancer: role of EGFR. BMC Complement Altern Med. 2011 Nov 09; 11:111.
    View in: PubMed
    Score: 0.065
  17. EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators. Mol Cancer Res. 2011 Jul; 9(7):960-75.
    View in: PubMed
    Score: 0.063
  18. Epidermal growth factor receptor is required for colonic tumor promotion by dietary fat in the azoxymethane/dextran sulfate sodium model: roles of transforming growth factor-{alpha} and PTGS2. Clin Cancer Res. 2009 Nov 15; 15(22):6780-9.
    View in: PubMed
    Score: 0.057
  19. Inducible heat shock protein 70 prevents multifocal flat dysplastic lesions and invasive tumors in an inflammatory model of colon cancer. Carcinogenesis. 2009 Jan; 30(1):175-82.
    View in: PubMed
    Score: 0.053
  20. Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clin Cancer Res. 2008 Apr 15; 14(8):2253-62.
    View in: PubMed
    Score: 0.051
  21. Inducible nitric oxide synthase (iNOS) mediates the early increase of blood supply (EIBS) in colon carcinogenesis. FEBS Lett. 2007 Aug 07; 581(20):3857-62.
    View in: PubMed
    Score: 0.048
  22. A vitamin D analogue inhibits colonic carcinogenesis in the AOM/DSS model. J Surg Res. 2007 Oct; 142(2):239-45.
    View in: PubMed
    Score: 0.048
  23. Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Res. 2007 Jan 15; 67(2):827-35.
    View in: PubMed
    Score: 0.047
  24. Chemoprevention of colon carcinogenesis by polyethylene glycol: suppression of epithelial proliferation via modulation of SNAIL/beta-catenin signaling. Mol Cancer Ther. 2006 Aug; 5(8):2060-9.
    View in: PubMed
    Score: 0.045
  25. Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. Cancer Res. 2006 Jun 01; 66(11):5656-64.
    View in: PubMed
    Score: 0.045
  26. Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation. FEBS Lett. 2005 Jul 04; 579(17):3497-502.
    View in: PubMed
    Score: 0.042
  27. Microsatellite analysis of sporadic flat and depressed lesions of the colon. Dig Dis Sci. 2005 Feb; 50(2):327-30.
    View in: PubMed
    Score: 0.041
  28. The nonsteroidal anti-inflammatory drug, nabumetone, differentially inhibits beta-catenin signaling in the MIN mouse and azoxymethane-treated rat models of colon carcinogenesis. Cancer Lett. 2005 Jan 20; 217(2):161-9.
    View in: PubMed
    Score: 0.041
  29. Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer. Cancer Res. 2003 Jul 01; 63(13):3517-23.
    View in: PubMed
    Score: 0.037
  30. Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin. Cancer Epidemiol Biomarkers Prev. 2002 Dec; 11(12):1653-62.
    View in: PubMed
    Score: 0.035
  31. Ursodeoxycholic acid inhibits the initiation and postinitiation phases of azoxymethane-induced colonic tumor development. Cancer Epidemiol Biomarkers Prev. 2002 Nov; 11(11):1316-21.
    View in: PubMed
    Score: 0.035
  32. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. Hum Pathol. 2000 Jun; 31(6):672-7.
    View in: PubMed
    Score: 0.029
  33. Inhibition of O(6)-methylguanine-DNA methyltransferase increases azoxymethane-induced colonic tumors in rats. Carcinogenesis. 1999 Dec; 20(12):2355-60.
    View in: PubMed
    Score: 0.028
  34. Ploidy as a prognostic feature in colonic adenocarcinoma. Arch Surg. 1996 Jun; 131(6):587-92.
    View in: PubMed
    Score: 0.022
  35. 1 alpha,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a noncalcemic analogue of 1 alpha,25-dihydroxyvitamin D3, inhibits azoxymethane-induced colonic tumorigenesis. Cancer Res. 1995 Jul 15; 55(14):3050-4.
    View in: PubMed
    Score: 0.021
  36. X-ray fluorescence microscopy demonstrates preferential accumulation of a vanadium-based magnetic resonance imaging contrast agent in murine colonic tumors. Mol Imaging. 2015; 14.
    View in: PubMed
    Score: 0.020
  37. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer. 1994 Dec 01; 74(11):2908-17.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.